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Abstract
Migraine is sexually dimorphic and associated in 20–30% of patients with an aura most likely caused by cortical spreading
depression (CSD). We have previously shown that systemic L-kynurenine (L-KYN), the precursor of kynurenic acid,
suppresses CSD and that this effect depends on the stage of the estrous cycle in female rats. The objectives here are to
determine the influence of ovarian hormones on KCl-induced CSD and its suppression after L-KYN by directly modulating
estradiol or progesterone levels in ovariectomized rats. Adult female rats were ovariectomized and subcutaneously
implanted with silastic capsules filled with progesterone or 17b-estradiol mixed with cholesterol, with cholesterol only or
left empty. Two weeks after the ovariectomy/capsule implantation, the animals received an i.p. injection of L-KYN (300 mg/
kg) or NaCl as control. Thirty minutes later CSDs were elicited by applying KCl over the occipital cortex and recorded by DC
electrocorticogram for 1 hour. The results show that both estradiol and progesterone increase CSD frequency after
ovariectomy. The suppressive effect of L-KYN on CSD frequency, previously reported in normal cycling females, is not found
anymore after ovariectomy, but reappears after progesterone replacement therapy. Taken together, these results
emphasize the complex role of sex hormones on cortical excitability. The CSD increase by estradiol and, more surprisingly,
progesterone may explain why clinically migraine with aura appears or worsens during pregnancy or with combined
hormonal treatments.
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Introduction
Migraine is the most common neurological disorder and occurs
in about 15% of the population with a female/male ratio of 3/1
[1]. The mechanisms of sexual dimorphism in migraine are not
well understood, but ovarian hormones, especially estrogens [2],
seem to play a key role. Indeed, migraine in women is influenced
by menarche, menstruation, pregnancy, menopause, oral contra-
ceptive use, and hormonal replacement therapy [3]. Sex steroids,
however, may differentially modulate migraine with aura (MA)
and without aura (MO). In contrast to MO, MA is favored by
hyperestrogenic states: it can appear during pregnancy [4] and is
worsened by oral contraceptives [5].
Strong evidence from clinical correlations with functional brain
imaging studies suggests that the migraine aura is due to cortical
spreading depression (CSD) originating in the occipital cortex [6].
CSD is a slowly progressing wave (3–5 mm/min) of neurono-glial
depolarization followed by a long-lasting suppression of neuronal
activity and excitability [7]. It has been shown that gonadal
steroids can modulate CSD susceptibility. In female mice CSD
thresholds are lower than in males [8]. Estrogens are considered
responsible for the higher CSD propagation velocity in Wistar
audiogenic rats [9]. The increased susceptibility to CSD of female
FHM1 knock-in mice is abolished by ovariectomy whereafter it is
partially restored by estradiol treatment [10].
Glutamate and glutamate receptors play a pivotal role in the
initiation and propagation of CSD. Glutamate and N-Methyl-D-
aspartate (NMDA) trigger CSD, while NMDA receptor antago-
nists inhibit CSD initiation and propagation [11]. We showed
previously that CSD is suppressed by systemic administration of L-
kynurenine (L-KYN) [12]. L-kynurenine is the precursor of
kynurenic acid that is an endogenous NMDA receptor antagonist
[13]. As kynurenic acid penetrates poorly the blood–brain barrier
[14], L-KYN is given systemically to rats to increase the brain
concentrations of kynurenic acid [15]. In our study, the CSD-
suppressive effect of L-KYN was more pronounced in females
than in males and in females it differed between the phases of the
estrous cycle [12].
In the present study, we have therefore investigated separately
the modulating effect of estrogen and progesterone on CSD
frequency in ovariectomized rats, as well as the influence of these
hormones on the CSD suppression by L-KYN.
Materials and Methods
Animals
A total of 66 female adult Sprague-Dawley rats were used in this
study. They were raised and maintained under standard
laboratory conditions, with tap water and regular rat chow
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available ad libitium on a 12-h dark 12-h light cycle. All animal
procedures and care complied with the guidelines of the
International Association for the Study of Pain and the European
Communities Council (86/609/ECC) and were approved by the
Ethics Committee of the Faculty of Medicine of Lie`ge University
(ethic protocol number 1233). All surgery was performed under
isoflurane or chloral hydrate anesthesia, and all efforts were made
to minimize suffering.
Ovariectomy and hormonal treatments
Animals were bilaterally ovariectomized under isoflurane
inhalation (2 to 3% in a flow of 1 l/min of oxygen, ForeneH,
Abbott, Queenborough, Kent, England) and subcutaneously
implanted with silastic capsules. Estrogen implants were 1 cm in
length and filled with a 20% 17b-estradiol-cholesterol mixture (E2;
Sigma-Aldrich, Steinheim, Germany; n = 18), whereas estrogen
control implants were 100% cholesterol (E2Cont; Sigma-Aldrich,
Steinheim, Germany, n= 16). Progesterone implants were 3 cm in
length and filled with 100% progesterone (P4; Sigma-Aldrich,
Steinheim, Germany, n= 16); empty capsules were used as
controls (P4Cont, n= 15). Implants of such lengths and concen-
trations are known to reproduce the physiological peak of
proestrus blood levels of hormones [16].
Experimental protocol
Two weeks after ovariectomy and capsule implantation, each of
the before described treatment groups were divided in a subgroup
receiving an intraperitoneal (i.p.) injection of 300 mg/kg of L-
kynurenine sulphate (‘‘L-KYN’’, Sigma, Steinheim, Germany; E2
L-KYN group n=9; E2Cont L-KYN n=8; P4 L-KYN n=8;
P4Cont L-KYN n=7) and another receiving physiological saline
(‘‘NaCl’’; E2 NaCl group n= 9; E2Cont NaCl n= 8; P4 NaCl
n= 8; P4Cont NaCl n= 8) injections as controls. The L-KYN dose
was chosen based on previous studies of cortical excitability
[12,17]. We started to elicit and record CSDs 30 minutes after the
i.p. injections.
CSDs were studied according to the method previously
described [18]. Briefly, anesthetized rats (chloral hydrate,
400 mg/kg) were placed in a stereotactic frame (David Kopf
Instruments, USA). Rectal temperature was maintained between
36.5 and 37.0uC using a thermostatically controlled heating
blanket (ATC 1000H, WPI Inc., USA), heart rate and blood
oxygen level were monitor with a rodent oximeter (Kent Scientific
corporation, USA). Three 1–2 mm wide burr holes were drilled
2 mm off the midline: 7 mm posterior to bregma (P-7; occipital
cortex; stimulation site), 4 mm posterior to bregma (P-4; occipito-
parietal recording site) and 1 mm anterior to bregma (A+1; frontal
recording site) [19].
We induced CSDs by placing a cotton ball soaked with 1 M
KCl over the pial surface at the stimulation site. Cortical direct
current (DC) potential shifts and the electrocorticogram were
recorded with Ag/AgCl electrodes. The electrical signals were
amplified with an ISODAM-8A bioamplifier at a DC-10 kHz
band width (WPI Inc, USA), digitized at a 200 Hz sampling rate
and stored for off-line analysis using Micro1401 MKII and Spike2
software (CED Co., UK). CSDs were counted for 1 hour at the
parieto-occipital and frontal recording sites and the results were
expressed as CSD frequency per hour. Propagation velocity
between parieto-occipital and frontal recording sites was calculat-
ed for the first CSD.
Statistical analysis
Group values were expressed as means 6 standard error of
means. To assess the effect of sexual hormones on L-KYN-
induced CSD changes, two-way ANOVA [treatment (NaCl/L-
KYN) x hormone (E2/E2Cont)] and [treatment (NaCl/L-KYN) x
hormone (P4/P4Cont)] was used followed by Duncan’s post-hoc
tests. Analyses were implemented in Statistica (Version 9 for
Windows) with p,0.05 as threshold for statistical significance.
Results
Influence of E2 on CSD frequency and its suppression by
L-KYN
At the parieto-occipital level, ovariectomized females treated
since 2 weeks with E2 had a higher CSD frequency than those
treated with cholesterol. This effect appears for the global
population (ANOVA hormone effects F(1,34) = 12.91, p= 0.001)
and, in particular, for NaCl treated females (Duncan’s test E2 vs
E2Cont, p = 0.001) (Fig.1). The same result was obtained at the
frontal recording site (Table 1). In NaCl groups, E2-treated
females had a greater number of CSDs than those treated only
with cholesterol (Duncan’s test E2Cont vs E2, p = 0.005). The
hormonal treatment had no influence on the propagation velocity
of the first CSD (ANOVA hormone effects F(1,34) = 0.46, N.S.).
L-KYN had no significant influence on CSD frequency in
ovariectomized females neither at the parieto-occipital site
(ANOVA treatment effect F(1,34) = 0.44, N.S.) (Fig.1), nor at the
frontal site (ANOVA treatment effects F(1,34) = 1.30, N.S.)
(Table 1). L-KYN numerically decreased parieto-occipital CSD
frequency in ovariectomized E2-treated animals (mean: 9.7/h vs
12.11 for NaCl), but this effect only tended to be significant
(Duncan’s test NaCl vs L-KYN, p= 0.078). L-KYN administration
had no significant effect on CSD propagation velocity (ANOVA
treatment effects F(1,34) = 3.33, N.S.) (Table 1).
Influence of P4 on CSD frequency and its suppression by
L-KYN
Implanted P4 capsules increased parieto-occipital CSD fre-
quency after 2 weeks compared to implanted capsules left empty.
This effect was significant for the global population of animals
(ANOVA hormone effects F(1,31) = 8.98, p = 0.006) and in NaCl-
treated females (Duncan’s test P4 vs P4Cont, p = 0.004) (Fig. 2). L-
KYN treatment significantly decreased parieto-occipital CSD
frequency in P4 treated rats (Duncan’s test NaCl vs L-KYN,
p= 0.013) while it had no effect on CSD frequency in NaCl
treated females.
By contrast, although progesterone numerically increased CSD
frequency at the frontal recording site, there was no significant
change after L-KYN treatment, neither of frontal CSD frequency
nor of propagation velocity of the first CSD (frontal CSD
frequency: ANOVA hormone effects F(1,31) = 0.11, N.S., AN-
OVA treatment effects F(1,31) = 1.42, N.S.; propagation velocity:
ANOVA hormone effects F(1,31) = 0.06, N.S., ANOVA treatment
effects F(1,31) = 0.42, N.S.) (Table 2).
Discussion
Our results demonstrate for the first time that treatment with
estradiol or progesterone in ovariectomized rats increases KCl-
induced CSD frequency. Moreover, we found that the suppressive
effect of systemic L-KYN administration on CSD previously
reported in normally cycling females disappears after ovariectomy,
but becomes apparent again after progesterone replacement
treatment, but not after estrogen administration. We will discuss
these two findings in sequence.
Ovarian Hormones Influence on CSD
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Influence of female hormones on CSD frequency
The results obtained in ovariectomized rats with or without
estrogen replacement therapy are in line with those reported in the
knock-in mouse model of familial hemiplegic migraine type 1 [10].
In mutant R192Q and S218L mice the increased CSD
susceptibility was decreased by ovariectomy and partially restored
by estrogen treatment. In our previous study of the effects of L-
KYN on CSD susceptibility, CSD frequency in NaCl-treated
cycling females was on average 10.75 [12], which is clearly
superior to the 7.13 and 7.63 frequency values found here in
ovariectomized control animals in E2 and P4 groups respectively.
This suggests that ovariectomy decreases CSD frequency in
normal female rats as it does in the FHM1 mutant mice [10]. At
variance with the latter is that in our study we found no effect of
sex hormones on CSD propagation velocity.
Estrogens can modify susceptibility to CSD by several
mechanisms, but mainly through their effect on glutamate
neurotransmission that is known to subtend CSD generation.
Estrogens affect neuronal plasticity during the estrous cycle by
increasing the number of dendritic spines [20] and synaptic
densities via an NMDA receptor dependent mechanism [21,22].
They upregulate NMDA receptors and downregulate glutamate
uptake by astrocytes [23,24].
Contrary to estrogens, progesterone is classically thought to
inhibit neuronal activity [25]. Progesterone can reduce cortical
NMDA receptor binding density [26] and its metabolite,
allopregnanolone, hyperpolarizes the neuronal membrane by
increasing GABA mediated chloride conductance. These effects
could decrease CSD susceptibility rather than increase it, as found
in our study after P4 replacement therapy. Despite the lack of a
clear-cut neurobiological explanation, at least one study found
results that are similar to ours. Sachs et al. (2007) reported in a
model of rat neocortical slices that addition of progesterone to the
medium increased CSD amplitude and frequency, leaving
propagation velocity unchanged. Progesterone had the same effect
as estrogen and both hormones also promoted long-term
potentiation [27]. In humans, there is only indirect evidence that
progesterone may enhance neuronal excitability. Excitability of
the motor cortex, as tested by transcranial magnetic stimulation,
was increased in women with the premenstrual syndrome during
the luteal phase when circulating progesterone levels were high
[28].
In the present study, progesterone increases significantly CSD
frequency at the parieto-occipital recording site, but only
numerically at the frontal site, while estrogen has a significant
enhancing effect at both recording sites. This difference may have
various explanations. In general, the number of CSDs tends to be
lower at the frontal than at the parieto-occipital recording site
because a number of occipitally-generated CSD waves do not
spread into the frontal cortex. Experimental interventions can
differentially influence CSD generation and its postero-anterior
propagation. For instance, we have found in a previous study [18]
that chronic valproate treatment in rat decreased frontal but not
parieto-occipital CSD frequency while lamotrigine had an
inhibitory effect at both sites. Progesterone could have an opposite
differential profile, increasing CSD generation close to the KCl
application site, but inhibiting CSD propagation to the frontal
recording site. The numerical, though non-significant, decrease of
CSD propagation velocity after progesterone would favor this
hypothesis. Alternatively, one may argue that the increase of
frontal CSDs induced by estrogen treatment is amplified because
of the low mean value of CSD frequency in the estrogen-control
group (5.25) respective to the progesterone-control group (7.75).
We do not think, however, that this is the explanation for the
difference in frontal CSDs between estrogen and progesterone
treatments. Also, the fact that the implanted silastic capsules were
filled with cholesterol in E2Cont, but left empty in P4Cont, cannot
explain this difference, since cholesterol would have influenced
CSD propagation both in the E2Cont and E2 groups. Moreover,
Figure 1. CSD frequency at the parieto-occipital site in rats treated with 17b-estradiol. Number of parieto-occipital CSD/hour in
ovariectomized female rats treated during two weeks with cholesterol (E2Cont) or 17b-estradiol (E2) after i.p. injection of L-KYN or NaCl (***p,0.001
Duncan’s test E2Cont NaCl vs E2 NaCl).
doi:10.1371/journal.pone.0082279.g001
Table 1. CSD frequency at the frontal recording site and CSD
propagation velocity in ovariectomized rats treated or not
with estradiol.
NaCl L-KYN
CSD frequency at frontal
recording site
E2Cont 5.2560.31 8.2560.68
E2 12.1161.09** 9.7860.76
CSD propagation velocity (mm/
min)
E2Cont 3.3460.27 3.0460.15
E2 3.2360.10 2.8660,18
**p,0.01 Duncan’s test E2Cont NaCl vs E2 NaCl; E2 L-KYN group n= 9; E2Cont
L-KYN n=8; E2 NaCl group n= 9; E2Cont NaCl n = 8.
doi:10.1371/journal.pone.0082279.t001
Ovarian Hormones Influence on CSD
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the presence of cholesterol had no influence on CSD occurrence,
as evidenced by the similar CSD frequency at the parieto-occipital
site in the estrogen and progesterone control groups (see figures 1
& 2).
CSD is thought to underlie aura symptoms [29] and the
influence of hormones on MA has been attributed to an effect on
CSD [25]. Our findings in rats are in line with data showing that
in women persistent high gonadal steroid levels are deleterious for
MA. During the first trimester of pregnancy, for instance, migraine
symptoms may worsen in women suffering from MA and MA
attacks may appear de novo during pregnancy [30]. Concordantly,
combined oral contraceptives tend to worsen MA symptoms or to
trigger the appearance of aura symptoms [5]. On the other hand,
progesterone-only contraceptive pills had a beneficial effect on
MA frequency and intensity in an observational prospective study
[31]. The effect, however, took 6 months to appear and was
observed only in women in whom MA onset was related to
previous use of combined oral contraceptives. In another
retrospective study of a mixed group of MO and MA patients
[32] contraception with desogestrel decreased on average migraine
frequency, intensity and use of any headache medication, except
triptans, but out of 43 patients 7 had an increase in headache
frequency. The weakness of both studies is the lack of a control
group of women without hormonal treatment.
Influence of female hormones on the suppression of CSD
by L-KYN
In a previous study we have shown that the sole systemic
administration of L-KYN at the same concentration as in the
present work has a suppressive effect on CSD frequency in female
rats, whereas in males we obtained such an effect only when L-
KYN was combined to probenecid, an amino-acid transporter
inhibitor increasing cerebral kynurenic acid concentrations [12].
The suppressive effect of L-KYN on CSD frequency is associated
with an increase in cerebral levels of kynurenic acid. This effect
varies with the phases of the estrous cycle. It is amplified during
diestrus when progesterone levels are low and estrogen levels only
start to raise [33], which indicates that sex hormones modulate the
suppressive effect of L-KYN on CSD. In the present study, we
have tested separately the effect of estradiol and progesterone on
the L-KYN-induced suppression of CSDs in ovariectomized
animals. While L-KYN is not different from NaCl in ovariecto-
mized control rats, it reduces significantly the increase in parieto-
occipital CSDs induced by progesterone replacement therapy and
tends to do so for the one induced by estrogen. The latter effect
does not reach the level of statistical significance probably due to
the large variance of data. We assume that the administration of
300 mg/kg L-KYN alone does not increase brain KYNA
sufficiently to inhibit CSD frequency in ovariectomized rats
without hormonal replacement treatment.
There could be several explanations for these findings. First,
estrogens are able to inhibit several enzymes involved in
tryptophan metabolism, in particular kynurenine aminotransferase
that synthesizes kynurenic acid from L-KYN [34,35]. Although
poorly studied, progesterone apparently does not inhibit kynurenic
acid synthesis [35]. If the effect of female hormones on kynurenic
acid metabolism would play a role, one would expect an enhanced
inhibition of CSDs by L-KYN after ovariectomy, which is clearly
not the case. Secondly, after ovariectomy there is no finely tuned
cycling of hormone levels anymore. This is at variance with
normally cycling females where the hormonal variations induce a
number of genomic and non-genomic regulations in combination
[36]. Moreover, in normal cycling females it is the interaction
between estrogen and progesterone that shapes synaptic plasticity,
glutamatergic neurotransmission and brain excitability (see above)
[37]. The lack of a similar cycle-dependent interaction in
ovariectomized rats without hormonal replacement treatment
may contribute to the loss of significant CSD suppression by L-
Figure 2. CSD frequency at the parieto-occipital site in rats treated with progesterone. Number of parieto-occipital CSD/hour in
ovariectomized female rats treated during two weeks with progesterone (P4) or with empty capsules (P4Cont) after i.p. injection of L-KYN or NaCl (**
p,0.01 Ducan’s test P4 NaCl vs P4Cont NaCl; # p,0.05 P4 NaCl vs P4 L-KYN).
doi:10.1371/journal.pone.0082279.g002
Table 2. CSD frequency at the frontal recording site and CSD
propagation velocity in ovariectomized rats treated or not
with progesterone.
NaCl L-KYN
CSD frequency at frontal
recording site
P4Cont 7.7560.79 7.8660.40
P4 8.7560.49 7.2560.75
CSD propagation velocity
(mm/min)
P4Cont 3.3160.26 3.3661.80
P4 3.0960.25 3.3860.16
P4 L-KYN n= 8; P4Cont L-KYN n= 7; P4 NaCl n = 8; P4Cont NaCl n = 8.
doi:10.1371/journal.pone.0082279.t002
Ovarian Hormones Influence on CSD
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KYN, whereas with hormonal treatments the suppressive effect of
L-KYN reappears or tends to reappear. Since L-KYN, i.e.
kynurenic acid, modulates CSDs most likely by blocking NMDA
receptors [13] and both estrogen and progesterone can modify
these receptors [21–26], it seems plausible that the hormonal
effects on L-KYN-induced CSD suppression are mediated via
NMDA receptor changes. This hypothesis can be tested in a future
study using NMDA receptor antagonists. Finally, as discussed
above, in ovariectomized animals CSD frequency is markedly
decreased compared to normal cycling rats whichever of the phase
of the estrous cycle is considered [12]. The lack of a supplementary
decrease of CSD frequency by L-KYN in ovariectomized rats
without hormonal replacement might thus also be due to the fact
that after ovariectomy a ‘‘floor’’ is reached beyond which no
further effect can be expected from a compound acting on
glutamate transmission. This would also account for the
reappearance of some visible effect of L-KYN after the before-
discussed enhancing effect on CSD frequency by estradiol or
progesterone treatment.
Conclusion
Hormone-dependent changes in cortical excitability contribute
to the sexual dimorphism of migraine. We confirm here that
ovariectomy in female rats decreases CSD frequency as well as the
suppressive effect of L-KYN on CSD. We show in addition that
both estrogen and progesterone replacement therapies increase
CSD frequency and that progesterone restores the CSD inhibition
by L-KYN. Taken together these results underscore the complex
role of ovarian hormones in CSD susceptibility, and thus in
migraine with aura, providing novel aspects to be taken into
consideration for its management.
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